Company profile
Rising Biosciences, Inc.
OTC: RBII · Healthcare · Medical - Pharmaceuticals
#893 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
——FH —DQ —GM —SS 47
v0.1 · 5/100 weight · pillars only
↑ operating margin, revenue growth (YoY) · ↓ disclosure history, market scale
Methodology →Revenue TTM
$782.3k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
$49.8k
Employees
—
as of 2026-08-03
Market cap
$5.0k
as of 2026-08-03
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$782.3k$782.3k2020
Net income$49.8k$49.8k2020
Operating income$284.2k$284.2k2020
Total assets$640.4k$640.4k2020
Liabilities$1.7M$1.7M2020
Equity-$1.1M-$1.1M2020
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Rising Biosciences, Inc.’s revenue?
Rising Biosciences, Inc. booked $782.3k in FY2020 revenue, growing 378% year over year — faster than 93% of Healthcare companies we track, at a 6.4% net margin.
Peers · Healthcare
BioCorRx Inc.44DSeres Therapeutics, Inc.52DHerborium Group, Inc.36DTivic Health Systems, Inc.34DParadigm Medical Industries, Inc.——Guided Therapeutics, Inc.42DNeighbors
Sheridan →Key facts
CEOArthur Hall
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersSheridan, WY
ExchangeOTC: RBII
Employees—
IPO date2000-08-17
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.